Sonja J van der Veen1, Ghazaleh Ghobadi1, Rudolf A de Boer2, Hette Faber1, Megan V Cannon2, Peter W Nagle1, Sytze Brandenburg3, Johannes A Langendijk4, Peter van Luijk4, Robert P Coppes5. 1. Department of Cell Biology, University Medical Center Groningen, University of Groningen, The Netherlands; Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands. 2. Department of Experimental Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands. 3. Kernfysisch Versneller Instituut, Groningen, The Netherlands. 4. Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands. 5. Department of Cell Biology, University Medical Center Groningen, University of Groningen, The Netherlands; Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, The Netherlands. Electronic address: r.p.coppes@umcg.nl.
Abstract
BACKGROUND AND PURPOSE: In thoracic irradiation, the maximum radiation dose is restricted by the risk of radiation-induced cardiopulmonary damage and dysfunction limiting tumor control. We showed that radiation-induced sub-clinical cardiac damage and lung damage in rats mutually interact and that combined irradiation intensifies cardiopulmonary toxicity. Unfortunately, current clinical practice does not include preventative measures to attenuate radiation-induced lung or cardiac toxicity. Here, we investigate the effects of the ACE inhibitor captopril on radiation-induced cardiopulmonary damage. MATERIAL AND METHODS: After local irradiation of rat heart and/or lungs captopril was administered orally. Cardiopulmonary performance was assessed using biweekly breathing rate measurements. At 8 weeks post-irradiation, cardiac hemodynamics were measured, CT scans and histopathology were analyzed. RESULTS: Captopril significantly improved breathing rate and cardiopulmonary density/structure, but only when the heart was included in the radiation field. Consistently, captopril reduced radiation-induced pleural and pericardial effusion and cardiac fibrosis, resulting in an improved left ventricular end-diastolic pressure only in the heart-irradiated groups. CONCLUSION: Captopril improves cardiopulmonary morphology and function by reducing acute cardiac damage, a risk factor in the development of radiation-induced cardiopulmonary toxicity. ACE inhibition should be evaluated as a strategy to reduce cardiopulmonary complications induced by radiotherapy to the thoracic area.
BACKGROUND AND PURPOSE: In thoracic irradiation, the maximum radiation dose is restricted by the risk of radiation-induced cardiopulmonary damage and dysfunction limiting tumor control. We showed that radiation-induced sub-clinical cardiac damage and lung damage in rats mutually interact and that combined irradiation intensifies cardiopulmonary toxicity. Unfortunately, current clinical practice does not include preventative measures to attenuate radiation-induced lung or cardiac toxicity. Here, we investigate the effects of the ACE inhibitor captopril on radiation-induced cardiopulmonary damage. MATERIAL AND METHODS: After local irradiation of rat heart and/or lungs captopril was administered orally. Cardiopulmonary performance was assessed using biweekly breathing rate measurements. At 8 weeks post-irradiation, cardiac hemodynamics were measured, CT scans and histopathology were analyzed. RESULTS:Captopril significantly improved breathing rate and cardiopulmonary density/structure, but only when the heart was included in the radiation field. Consistently, captopril reduced radiation-induced pleural and pericardial effusion and cardiac fibrosis, resulting in an improved left ventricular end-diastolic pressure only in the heart-irradiated groups. CONCLUSION:Captopril improves cardiopulmonary morphology and function by reducing acute cardiac damage, a risk factor in the development of radiation-induced cardiopulmonary toxicity. ACE inhibition should be evaluated as a strategy to reduce cardiopulmonary complications induced by radiotherapy to the thoracic area.
Authors: Marjan Boerma; Gregory A Nelson; Vijayalakshmi Sridharan; Xiao-Wen Mao; Igor Koturbash; Martin Hauer-Jensen Journal: World J Cardiol Date: 2015-12-26
Authors: Terence T Sio; Pamela J Atherton; Levi D Pederson; W Ken Zhen; Robert W Mutter; Yolanda I Garces; Daniel J Ma; James L Leenstra; Jean-Claude M Rwigema; Shaker Dakhil; James D Bearden; Sonja J van der Veen; Apar K Ganti; Steven E Schild; Robert C Miller Journal: Int J Radiat Oncol Biol Phys Date: 2018-11-02 Impact factor: 7.038
Authors: Elizabeth R Jacobs; Jayashree Narayanan; Brian L Fish; Feng Gao; Leanne M Harmann; Carmen Bergom; Tracy Gasperetti; Jennifer L Strande; Meetha Medhora Journal: Health Phys Date: 2019-04 Impact factor: 1.316
Authors: Meetha Medhora; Feng Gao; Tracy Gasperetti; Jayashree Narayanan; Abdul Hye Khan; Elizabeth R Jacobs; Brian L Fish Journal: Health Phys Date: 2019-04 Impact factor: 1.316
Authors: Keith Unger; Yaoxiang Li; Celine Yeh; Ana Barac; Monvadi B Srichai; Elizabeth A Ballew; Michael Girgis; Meth Jayatilake; Vijayalakshmi Sridharan; Marjan Boerma; Amrita K Cheema Journal: Radiother Oncol Date: 2020-04-20 Impact factor: 6.280
Authors: Mohamad B Dabjan; Carolyn Ms Buck; Isabel L Jackson; Zeljko Vujaskovic; Brian Marples; Julian D Down Journal: Lab Invest Date: 2016-08-01 Impact factor: 5.662
Authors: Umesh C Sharma; Swati D Sonkawade; Joseph A Spernyak; Sandra Sexton; Juliane Nguyen; Suraj Dahal; Kristopher M Attwood; Anurag K Singh; Jop H van Berlo; Saraswati Pokharel Journal: Circ Heart Fail Date: 2018-08 Impact factor: 8.790
Authors: Zachary S Morris; Sandeep Saha; William J Magnuson; Brett A Morris; Jenna F Borkenhagen; Alisa Ching; Gayle Hirose; Vanesa McMurry; David M Francis; Paul M Harari; Rick Chappell; Stuart Tsuji; Mark A Ritter Journal: Cancer Date: 2016-05-20 Impact factor: 6.860